These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28011623)

  • 1. Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.
    Wragg JW; Heath VL; Bicknell R
    Cancer Res; 2017 Feb; 77(4):1008-1020. PubMed ID: 28011623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraising antiangiogenic therapy for breast cancer.
    Kerbel RS
    Breast; 2011 Oct; 20 Suppl 3(0 3):S56-60. PubMed ID: 22015294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
    Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice.
    Maione F; Capano S; Regano D; Zentilin L; Giacca M; Casanovas O; Bussolino F; Serini G; Giraudo E
    J Clin Invest; 2012 May; 122(5):1832-48. PubMed ID: 22484816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.
    Shojaei F; Simmons BH; Lee JH; Lappin PB; Christensen JG
    Cancer Lett; 2012 Jul; 320(1):48-55. PubMed ID: 22269210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model.
    Tanaka Y; Shibata MA; Morimoto J; Otsuki Y
    Anticancer Res; 2011 Apr; 31(4):1225-34. PubMed ID: 21508369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence.
    Wang D; Xiao F; Feng Z; Li M; Kong L; Huang L; Wei Y; Li H; Liu F; Zhang H; Zhang W
    Breast Cancer Res; 2020 Sep; 22(1):103. PubMed ID: 32993785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
    Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
    Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
    Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
    Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.
    Elgebaly A; Menshawy A; El Ashal G; Osama O; Ghanem E; Omar A; Negida A
    Breast Dis; 2016 Jul; 36(2-3):91-101. PubMed ID: 27612040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs.
    Guerin E; Man S; Xu P; Kerbel RS
    Cancer Res; 2013 May; 73(9):2743-8. PubMed ID: 23610448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry.
    Sun H; Zhang D; Yao Z; Lin X; Liu J; Gu Q; Dong X; Liu F; Wang Y; Yao N; Cheng S; Li L; Sun S
    Cancer Biol Ther; 2017 Apr; 18(4):205-213. PubMed ID: 28278077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma.
    Su SC; Hu X; Kenney PA; Merrill MM; Babaian KN; Zhang XY; Maity T; Yang SF; Lin X; Wood CG
    Clin Cancer Res; 2013 Dec; 19(23):6461-72. PubMed ID: 24122794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
    Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
    BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
    Rovida A; Castiglioni V; Decio A; Scarlato V; Scanziani E; Giavazzi R; Cesca M
    Mol Cancer Ther; 2013 Oct; 12(10):2237-47. PubMed ID: 23918831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
    Mena AC; Pulido EG; Guillén-Ponce C
    Anticancer Drugs; 2010 Jan; 21 Suppl 1():S3-11. PubMed ID: 20110785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
    Anglesio MS; George J; Kulbe H; Friedlander M; Rischin D; Lemech C; Power J; Coward J; Cowin PA; House CM; Chakravarty P; Gorringe KL; Campbell IG; ; Okamoto A; Birrer MJ; Huntsman DG; de Fazio A; Kalloger SE; Balkwill F; Gilks CB; Bowtell DD
    Clin Cancer Res; 2011 Apr; 17(8):2538-48. PubMed ID: 21343371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives.
    Joosten SC; Hamming L; Soetekouw PM; Aarts MJ; Veeck J; van Engeland M; Tjan-Heijnen VC
    Biochim Biophys Acta; 2015 Jan; 1855(1):1-16. PubMed ID: 25446042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIF-1 Dimerization Inhibitor Acriflavine Enhances Antitumor Activity of Sunitinib in Breast Cancer Model.
    Yin T; He S; Shen G; Wang Y
    Oncol Res; 2014; 22(3):139-45. PubMed ID: 26168132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.